The fact that epigenetic treatments did not negatively influence CFTR expression, but even SAM treatment increased its expression in both CFBE and CF primary cells, reasonably excludes the undesirable effect of worsening any residual activity that CFTR could possibly retain even if mutated. The gene discussed is CFTR; the disease is cystic fibrosis.